Compare Garmin Ltd. (GRMN) vs Moderna, Inc. (MRNA) Price & Performance

Garmin (GRMN) trades at $276.16, down 1.09% today, showing strong fundamentals with consistent earnings beats and robust profitability. The company maintains impressive gross margins of 60.08% and net income margins of 24.47%, supported by steady revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive developments include multiple product awards and new feature rollouts across marine, fitness, and automotive segments, though technical indicators suggest near-term bearish pressure.

Garmin presents a compelling investment case with strong financial performance and analyst consensus target of $320.25 (16% upside). However, elevated valuation ratios (P/E 28.5, P/S 6.97) and technical bearish signals warrant caution. Key risks include competitive pressures in wearable technology and potential economic sensitivity in consumer discretionary spending.

Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.

Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.